Search details
1.
Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
J Allergy Clin Immunol
; 152(4): 984-996.e10, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37390899
2.
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
Br J Haematol
; 201(6): 1116-1124, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37004981
3.
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Haematologica
; 107(12): 2859-2869, 2022 12 01.
Article
in English
| MEDLINE | ID: mdl-35615931
4.
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Br J Haematol
; 194(2): 393-402, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34195988
5.
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
Br J Haematol
; 187(3): 337-346, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31271217
6.
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Blood
; 129(7): 846-854, 2017 02 16.
Article
in English
| MEDLINE | ID: mdl-27932374
7.
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Cancer
; 124(14): 2956-2963, 2018 07 15.
Article
in English
| MEDLINE | ID: mdl-29723417
8.
Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.
Br J Haematol
; 180(3): 356-364, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29265184
9.
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Cancer
; 123(22): 4403-4410, 2017 Nov 15.
Article
in English
| MEDLINE | ID: mdl-28743166
10.
Neutropenia in Patients with Common Variable Immunodeficiency: a Rare Event Associated with Severe Outcome.
J Clin Immunol
; 37(7): 715-726, 2017 Oct.
Article
in English
| MEDLINE | ID: mdl-28842786
11.
Severe chronic primary neutropenia in adults: report on a series of 108 patients.
Blood
; 126(14): 1643-50, 2015 Oct 01.
Article
in English
| MEDLINE | ID: mdl-26261239
12.
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.
Haematologica
; 102(8): 1368-1377, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28522576
13.
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.
Blood
; 123(23): 3574-7, 2014 Jun 05.
Article
in English
| MEDLINE | ID: mdl-24687085
14.
A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Am J Hematol
; 89(11): 1024-9, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-25052698
15.
Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.
Br J Haematol
; 182(1): 148-152, 2018 07.
Article
in English
| MEDLINE | ID: mdl-28485070
16.
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
N Engl J Med
; 363(26): 2511-21, 2010 Dec 23.
Article
in English
| MEDLINE | ID: mdl-21175313
17.
Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine.
Blood Adv
; 7(15): 3978-3983, 2023 08 08.
Article
in English
| MEDLINE | ID: mdl-36129842
18.
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.
Pharmaceutics
; 14(8)2022 Aug 12.
Article
in English
| MEDLINE | ID: mdl-36015302
19.
Long-term consequences of Hodgkin lymphoma therapy on T-cell lymphopoiesis.
J Allergy Clin Immunol
; 135(3): 818-20.e4, 2015 Mar.
Article
in English
| MEDLINE | ID: mdl-25420683
20.
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Leukemia
; 35(8): 2332-2345, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33483613